Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Generate Biomedicines, Inc.
No splits on record
Nothing in GENB's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Revenue | $31.89M | $20.46M |
| YoY Growth | 55.9% | - |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $31.89M | $20.46M |
| Gross Margin | 100.0% | 100.0% |
| Research and Development | $224.7M | $175.31M |
| Selling, General, and Administrative | $42.26M | $42.09M |
| Other | $0 | $0 |
| Total Operating Expenses | $266.96M | $217.4M |
| Operating Income (EBIT) | -$235.06M | -$196.94M |
| Operating Margin | -737.0% | -962.6% |
| Interest Expense | $1.14M | $2.12M |
| Interest Income | $13.66M | $18.12M |
| Other Income (Expense) | $12.26M | $15.77M |
| Income Before Tax (EBT) | -$222.8M | -$181.17M |
| Income Tax Expense | $163K | $212K |
| Net Income | -$203.15M | -$173.77M |
| Net Income Margin | -637.0% | -849.4% |
| Supplementary Data | ||
| EPS | -4.98 | -1.68 |
| Diluted EPS | -4.98 | -1.68 |
| Weighted Average OS | 50.09M | 127.45M |
| EBITDA | -$208.49M | -$163.71M |
| EBITDA Margin | -653.7% | -800.2% |
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Assets | ||
| Current Assets | ||
| Cash and Cash Equivalents | $121.65M | $176.27M |
| Short-Term Investments | $99.85M | $217.36M |
| Cash and Short-Term Investments | $221.5M | $393.63M |
| Accounts Receivable | $0 | $308K |
| Inventory | $0 | $0 |
| Other Current Assets | $12.87M | $13.56M |
| Total Current Assets | $234.37M | $407.49M |
| Long-Term Assets | ||
| Property, Plant & Equipment Net | $89.01M | $101.07M |
| Goodwill | $0 | $0 |
| Intangible Assets | $0 | $0 |
| Long-Term Investments | $0 | $0 |
| Deferred Tax Assets | $0 | $0 |
| Other Long-Term Assets | $6.81M | $9.7M |
| Total Long-Term Assets | $95.82M | $110.77M |
| Other Assets | $0 | $0 |
| Total Assets | $330.18M | $518.26M |
| Liabilities | ||
| Current Liabilities | ||
| Accounts Payable | $3.84M | $5.67M |
| Short-Term Debt | $0 | $0 |
| Current Income Tax Payable | $0 | $0 |
| Current Unearned Revenue | $21.19M | $42.42M |
| Other Current Liabilities | $16.43M | $15.78M |
| Total Current Liabilities | $82.2M | $86.63M |
| Long-Term Liabilities | ||
| Long-Term Debt | $0 | $0 |
| Long-Term Unearned Revenue | $4.51M | $15.17M |
| Long-Term Deferred Tax Liabilities | $0 | $0 |
| Other Long-Term Liabilities | $813.15M | $791.29M |
| Total Long-Term Liabilities | $871.18M | $866.72M |
| Other Liabilities | $0 | $0 |
| Total Liabilities | $953.38M | $953.35M |
| Stockholders' Equity | ||
| Preferred Stock | $0 | $0 |
| Common Stock | $50K | $50K |
| Retained Earnings | -$676.29M | -$473.14M |
| Comprehensive Income & Other | $106K | $118K |
| Other Stockholders' Equity | $60.28M | $38.57M |
| Total Equity | -$615.97M | -$434.52M |
| Minority Interest | -$7.23M | -$571K |
| Total Liabilities and Equity | $337.41M | $518.83M |
| Supplementary Data | ||
| Total Debt | $68.53M | $76.97M |
| Net Debt | -$53.12M | -$99.3M |
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Operating Activities | ||
| Net Income | -$222.97M | -$181.38M |
| Depreciation & Amortization | $13.18M | $15.35M |
| Deferred Income Tax | $0 | $0 |
| Stock-Based Compensation | $20.58M | $19.46M |
| Changes in Working Capital: | ||
| Accounts Receivable | $308K | -$213K |
| Inventory | $0 | $0 |
| Accounts Payable | -$2.13M | $3.5M |
| Other Working Capital | -$12.79M | $24.83M |
| Total Working Capital Change | -$14.62M | $28.12M |
| Other Non-Cash Items | $3.21M | $702K |
| Net Cash from Operating | -$200.62M | -$117.75M |
| Investing Activities | ||
| Capital Expenditures | -$3.51M | -$3.45M |
| Acquisitions | $0 | $0 |
| Purchases of Investments | -$164.73M | -$282.98M |
| Sales of Investments | $285.01M | $228.69M |
| Other Investing Activities | $0 | $10K |
| Net Cash from Investing | $116.77M | -$57.73M |
| Financing Activities | ||
| Debt Repaid | $8.16M | $11.12M |
| Common Stock Issuance | $0 | $0 |
| Common Stock Repurchases | $0 | $0 |
| Dividends Paid | $0 | $0 |
| Other Financing Activities | $14.25M | $6.13M |
| Net Cash from Financing | $28.06M | $91.33M |
| Forex Effect | $0 | $0 |
| Net Change in Cash | -$55.79M | -$84.15M |
| Supplementary Data | ||
| Operating Cash Flow | -$200.62M | -$117.75M |
| Capital Expenditure | -$3.51M | -$3.45M |
| Free Cash Flow | -$204.13M | -$121.2M |
| Cash at Beginning | $181.83M | $265.98M |
| Cash at End | $126.04M | $181.83M |